

Global Meningococcal Vaccines Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Meningococcal Vaccines Market Report and Forecast 2023-2031

Global Meningococcal Vaccines Market Outlook:

The global meningococcal vaccines market value was USD 3.45 billion in 2022, driven by the increasing prevalence of meningococcal disease across the globe. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2023-2031 to achieve a value of USD 6.24 billion by 2031.

Introduction

Meningococcal vaccines are designed to protect against meningococcal disease, which is caused by the bacterium *Neisseria meningitidis*. Meningococcal disease can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection), both of which can be life-threatening. Meningococcal vaccines stimulate the immune system to produce an immune response against the bacteria, providing protection against the disease.

Key Trends in the Meningococcal Vaccines Market

Some key trends involved in the meningococcal vaccines market are as follows:

- **Increasing Global Immunization Efforts:** There is a growing emphasis on immunization programs worldwide to combat meningococcal disease. Governments and healthcare organizations are promoting routine immunization of infants and adolescents to reduce the incidence of the disease. This trend is driven by the recognition of the public health impact of meningococcal infections and the availability of effective vaccines.
- **Expansion of Vaccine Coverage:** In recent years, there has been an expansion in the number of countries including meningococcal vaccines in their national immunization schedules. This includes both developed and developing countries, with an aim to protect vulnerable populations and prevent outbreaks. The focus is on providing access to vaccines to those at highest risk, such as infants, adolescents, and individuals living in high-risk areas or participating in certain activities (e.g., travel, military service).
- **Advancements in Vaccine Technology:** The development of new meningococcal vaccines and advancements in vaccine technology are driving the market. These include the introduction of conjugate vaccines, which offer broader protection against

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

multiple serogroups of *Neisseria meningitidis*. Conjugate vaccines have demonstrated enhanced immunogenicity and longer-lasting protection compared to earlier generations of vaccines. Additionally, efforts are underway to develop vaccines that provide protection against emerging serogroups and to improve the efficacy and duration of immune response.

-□ Focus on Serogroup B Vaccines: Serogroup B of *Neisseria meningitidis* has historically posed a challenge for vaccine development due to its complex polysaccharide structure. However, there have been significant advancements in the development of serogroup B vaccines, including the use of novel approaches such as recombinant protein-based vaccines and outer membrane vesicle vaccines. This has opened up new possibilities for providing protection against this particular serogroup.

Meningococcal Vaccines Market Segmentations

Market Breakup by Type

- Mono Vaccines
- Combination Vaccines

Market Breakup by Age Group

- Infants
- Childrens
- Adults

Market Breakup by Brand

- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others

Market Breakup by End User

- Hospitals
- Homecare
- Specialty Clinics
- Others

Market Breakup by Distribution Channel

- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others

Market Breakup by Region

- North America
- United States of America
- Canada

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Europe
- United Kingdom
- Germany
- France
- Italy
- Others

- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others

- Latin America
- Brazil
- Argentina
- Mexico
- Others

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Meningococcal Vaccines Market Scenario

The global market for meningococcal vaccines is experiencing significant growth due to the increasing incidence of meningococcal disease and the growing awareness about the importance of vaccination. Meningococcal disease is a serious public health concern, and the demand for effective vaccines is driving the market growth.

Several factors contribute to the market expansion. First, governments and healthcare organizations are implementing robust immunization programs to prevent meningococcal infections. This includes the incorporation of meningococcal vaccines into national immunization schedules and the promotion of routine vaccination for at-risk populations. This focus on immunization is creating a favourable market environment for meningococcal vaccines.

Geographically, the market for meningococcal vaccines is witnessing growth across regions. Developed countries have well-established immunization programs, while developing countries are expanding their vaccination efforts to combat the disease burden. Additionally, travel-related vaccinations and initiatives aimed at preventing outbreaks in high-risk areas contribute to the market growth.

Meningococcal Vaccines Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Johnson & Johnson Private Limited
- Mylan N.V.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- []Sun Pharmaceutical Industries Limited
- []Sanofi S.A.
- []Merck & Co., Inc.
- []GSK plc.
- []Novartis AG
- []AbbVie Inc.
- [] Fresenius Kabi AG
- []Amneal Pharmaceuticals LLC.
- []Pfizer Inc.
- []Serum Institute of India Pvt. Ltd.
- []Incepta Pharmaceuticals Ltd.
- []Walvax Biotechnology Co., Ltd.
- []Bio-Manguinhos

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Meningococcal Vaccines Market Overview
 - 3.1 Global Meningococcal Vaccines Market Historical Value (2016-2022)
 - 3.2 Global Meningococcal Vaccines Market Forecast Value (2023-2031)
- 4 Global Meningococcal Vaccines Market Landscape
 - 4.1 Global Meningococcal Vaccines Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Meningococcal Vaccines Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by End User
 - 4.2.3 Analysis by Major Regions
- 5 Global Meningococcal Vaccines Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3 Porter's Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Meningococcal Vaccines Market Segmentation
 - 6.1 Global Meningococcal Vaccines Market by Type
 - 6.1.1 Market Overview
 - 6.1.2 Mono Vaccines
 - 6.1.3 Combination Vaccines
 - 6.2 Global Meningococcal Vaccines Market by Age Group
 - 6.2.1 Market Overview
 - 6.2.2 Infants
 - 6.2.3 Childrens
 - 6.2.4 Adults
 - 6.3 Global Meningococcal Vaccines Market by Brand
 - 6.3.1 Market Overview
 - 6.3.2 Menactra
 - 6.3.3 Menveo
 - 6.3.4 Nimenrix
 - 6.3.5 Trumenba
 - 6.3.6 Bexsero
 - 6.3.7 Others
 - 6.4 Global Meningococcal Vaccines Market by End User
 - 6.4.1 Market Overview
 - 6.4.2 Hospitals
 - 6.4.3 Homecare
 - 6.4.4 Specialty Clinics
 - 6.4.5 Others
 - 6.5 Global Meningococcal Vaccines Market by Distribution Channel
 - 6.5.1 Market Overview
 - 6.5.2 Hospital Pharmacy
 - 6.5.3 Online Pharmacy
 - 6.5.4 Retail Pharmacy
 - 6.5.5 Others
 - 6.6 Global Meningococcal Vaccines Market by Region
 - 6.6.1 Market Overview
 - 6.6.2 North America
 - 6.6.3 Europe
 - 6.6.4 Asia Pacific
 - 6.6.5 Latin America
 - 6.6.6 Middle East and Africa
- 7 North America Meningococcal Vaccines Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Meningococcal Vaccines Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Meningococcal Vaccines Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia
 - 9.7 Others
- 10 Latin America Meningococcal Vaccines Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Meningococcal Vaccines Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
 - 14.1 Analysis by Funding Instances
 - 14.2 Analysis by Type of Funding
 - 14.3 Analysis by Funding Amount

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Regulatory Framework
 - 16.1 Regulatory Overview
 - 16.1.1 US FDA
 - 16.1.2 EU EMA
 - 16.1.3 INDIA CDSCO
 - 16.1.4 JAPAN PMDA
 - 16.1.5 Others
- 17 Supplier Landscape
 - 17.1 Johnson & Johnson Private Limited
 - 17.1.1 Financial Analysis
 - 17.1.2 Product Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisitions
 - 17.1.5 Certifications
 - 17.2 Mylan N.V.
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 Sun Pharmaceutical Industries Limited
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisitions
 - 17.3.5 Certifications
 - 17.4 Sanofi S.A.
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
 - 17.5 Merck & Co., Inc.
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisitions
 - 17.5.5 Certifications
 - 17.6 GSK plc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Novartis AG
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions
 - 17.7.5 Certifications
- 17.8 AbbVie Inc.
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 Fresenius Kabi AG
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisitions
 - 17.9.5 Certifications
- 17.10 Amneal Pharmaceuticals LLC.
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications
- 17.11 Pfizer Inc.
 - 17.11.1 Financial Analysis
 - 17.11.2 Product Portfolio
 - 17.11.3 Demographic Reach and Achievements
 - 17.11.4 Mergers and Acquisitions
 - 17.11.5 Certifications
- 17.12 Serum Institute of India Pvt. Ltd.
 - 17.12.1 Financial Analysis
 - 17.12.2 Product Portfolio
 - 17.12.3 Demographic Reach and Achievements
 - 17.12.4 Mergers and Acquisitions
 - 17.12.5 Certifications
- 17.13 Incepta Pharmaceuticals Ltd.
 - 17.13.1 Financial Analysis
 - 17.13.2 Product Portfolio
 - 17.13.3 Demographic Reach and Achievements
 - 17.13.4 Mergers and Acquisitions
 - 17.13.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.14 Walvax Biotechnology Co., Ltd.
 - 17.14.1 Financial Analysis
 - 17.14.2 Product Portfolio
 - 17.14.3 Demographic Reach and Achievements
 - 17.14.4 Mergers and Acquisitions
 - 17.14.5 Certifications
- 17.15 Bio-Manguinhos
 - 17.15.1 Financial Analysis
 - 17.15.2 Product Portfolio
 - 17.15.3 Demographic Reach and Achievements
 - 17.15.4 Mergers and Acquisitions
 - 17.15.5 Certifications
- 18 Global Meningococcal Vaccines Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Meningococcal Vaccines Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com